Indication intelligence, analysis and sector perception

RegMed’s close: mired in disappointment

December 9, 2015 5:57pm

It’s all about locking in profits for the year to come back at lower pricing. Read about it here …

Reporting from the World Stem Cell conference in Atlanta, Ge

I say what others won't, so you can do what others can't!

U.S. stocks gave up attempts at gains to close lower Wednesday, shaking off an earlier boost from news of a potential merger, as investors eyed a renewed decline in oil prices.

The NASDAQ closed DOWN -75.38 or -1.48% to 5,022.87 and the DOW closed DOWN -175.70 or -0.43% to 17,492.30.

Henry’omics:

The stem, cell and gene therapy RegMed sector stocks closed negative as I was traveling to Atlanta, Ge for the World Stem Cell conference (of 43 covered companies).

Volume was ho-hum.

My fear gauge is static – The CBOE Volatility Index (VIX) traded on Wednesday near 19.5 <having tripped 20> after Tuesday’s above 17 following Monday’s above 16!

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

The closing bell rang negative to end Wednesday’s session with an A/DL of 10/31 and 2 flats.

Wednesday’s trading indications – 1 hits/ 2 miss:

Bluebird bio (BLUE) closed UP – hit;
Kite Pharma (KITE) closed DOWN on news of offering – miss;
Harvard Apparatus RT (HART) closed DOWN – miss;

Riding the indexes and ETFs roller-coaster:

The iShares Biotechnology Stocks ETF (IBB) closed DOWN on Wednesday -5.39 or -1.63% after Tuesday’s advance of +6.31 or +1.95% following Monday’s decline of -7.44 or -2.24%

The NASDAQ Biotechnology index (NBI) closed Wednesday DOWN -55.96 or -1.62% after Tuesday’s advance of +63.05 or +1.86% following Monday’s -75.06 or -2.16%;

The Russell 2000 (IWM) closed Wednesday DOWN -1.30 or -1.13% after Tuesday’s decline of –0.64 or -0.55% following Monday’s decline of -1.77 or -1.50%;

The SPDR SD&P Biotech ETF (XBI) closed Wednesday DOWN -1.63 or -2.36% after Tuesday’s advance of +1.41 or +2.09% following Monday’s decline of -2.69 or -3.83%

Dosing the sector – what a day for the 43 Patients:

Closing bell: NEGATIVE with 31 decliners, 10 advancers and 2 flats

Who was UP – top 5:

bluebird bio (BLUE) closed up+$1.29 to $56.53;
ReNeuron (RENE.L) +$0.375 to $2.875;
Capricor (CAPR) +$0.19 to $3.88;
uniQure (QURE) +$0.08 to $18.00;
Mesoblast (MESO) closed up +$0.08 to $5.83;

Who closed down – top 5:

Kite Pharma (KITE) closed down -$4.81 to $70.04;
Spark Therapeutics (ONCE) -$3.54 to $46.77;
Juno Therapeutics (JUNO) -$2.49 to $46.70;
Aduro Biotech (ADRO) -$1.91 to $29.17;
Regenxbio (RGNX) closed down -$1.25 to $20.83

Flat:

Ocata Therapeutics (OCAT) at $8.48;
Cesca Therapeutics (KOOL) at $0.385

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.